You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
McKesson
AstraZeneca
Johnson and Johnson
Express Scripts

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 8,633,034

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,633,034
Title:Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
Abstract: This invention relates to methods for evaluating or inhibiting the aggregation of a protein in an aqueous suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution including sugar and a non-ionic surfactant.
Inventor(s): Trotter; Joseph T. (La Jolla, CA), Hamel; Jean-Bernard (Saint Cassien, FR), Carpenter; John Frank (Littleton, CO), Randolph; Theodore (Niwot, CO), Gabrielson; John Paul (Longmont, CO)
Assignee: Becton, Dickinson and Company (Franklin Lakes, NJ) The Regents of the University of Colorado (Denver, CO)
Application Number:12/739,009
Patent Claims:see list of patent claims

Details for Patent 8,633,034

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REOPRO abciximab INJECTABLE; INJECTION 103575 001 1994-12-22   Start Trial Becton, Dickinson and Company (Franklin Lakes, NJ) The Regents of the University of Colorado (Denver, CO) 2027-06-25 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Becton, Dickinson and Company (Franklin Lakes, NJ) The Regents of the University of Colorado (Denver, CO) 2027-06-25 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Becton, Dickinson and Company (Franklin Lakes, NJ) The Regents of the University of Colorado (Denver, CO) 2027-06-25 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12   Start Trial Becton, Dickinson and Company (Franklin Lakes, NJ) The Regents of the University of Colorado (Denver, CO) 2027-06-25 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 002 1998-05-12   Start Trial Becton, Dickinson and Company (Franklin Lakes, NJ) The Regents of the University of Colorado (Denver, CO) 2027-06-25 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 001 1998-06-19   Start Trial Becton, Dickinson and Company (Franklin Lakes, NJ) The Regents of the University of Colorado (Denver, CO) 2027-06-25 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Colorcon
Johnson and Johnson
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.